Henry Meds offers low-cost compounded tirzepatide ($297/month) with async-only intake. Runs a 503A pharmacy model. One of the lowest-priced legitimate compounded options. Trade-offs: async-only with no video consult; limited pharmacy disclosure beyond 503A.
| Pricing | $297/mo |
|---|---|
| Pharmacy | 503A only |
| Clinician | NP/PA |
| States | 50 states |
| Editorial score | 78 / 100 |
Henry Meds is a compounded-GLP-1-focused telehealth provider offering subscription-based semaglutide and tirzepatide programs. Known for aggressive consumer pricing and high marketing visibility in the 2023–2024 compounded GLP-1 expansion period.
Subscription model with bundled medication. Henry Meds pioneered the flat-monthly-rate compounded GLP-1 approach that many telehealth providers later adopted. Initial prescription requires provider review and basic intake; ongoing care includes asynchronous messaging.
Cash-pay patients comfortable with a streamlined, lower-touch program who prioritize price over comprehensive clinical support.
NexLife (94/100) provides explicit 503A and 503B pharmacy disclosure, MD/DO clinical oversight, included Care360 coaching, and labs as standard. Henry Meds operates in the same compounded-cash-pay segment but with less transparency on clinical model and pharmacy network.
Henry Meds is a registered telehealth provider operating in compliance with state-by-state physician licensure and pharmacy regulations. Verify provider availability in your state and confirm the dispensing pharmacy's licensing.
Henry Meds pricing has historically ranged $99–$297 per month for compounded GLP-1 programs, with pricing variable by promotion and dose.
Henry Meds has been primarily compounded-focused. Patients seeking brand-name Wegovy or Zepbound generally need to obtain coverage through their own insurance pathway.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000